Gatifloxacin Interference with Opiate Urine Drug Screen

2006 ◽  
Vol 26 (3) ◽  
pp. 435-439 ◽  
Author(s):  
Craig M Straley ◽  
Eric J Cecil ◽  
Mark P Herriman
Keyword(s):  
Drug Screen ◽  
Urine Drug Screen ◽  
Urine Drug

scholarly journals Evaluation of an opioid risk mitigation initiative for veterans undergoing hip or knee arthroplasty at San Francisco Veterans Affairs Heath Care System

2020 ◽  
Author(s):  
Tessa Rife ◽  
Christina Tat ◽  
Mahsa Malakootian
Keyword(s):  
San Francisco ◽  
Knee Arthroplasty ◽  
Risk Mitigation ◽  
Opioid Therapy ◽  
Veterans Affairs ◽  
Drug Screen ◽  
Urine Drug Screen ◽  
Urine Drug ◽  
Medication Disposal ◽  
Urine Drug Screening

Abstract Purpose Guidelines recommend evaluating the risk of opioid-related adverse events prior to initiating opioid therapy. The orthopedic service at San Francisco Veterans Affairs Health Care System (SFVHCS) has not routinely used risk assessment tools such as the Stratification Tool for Opioid Risk Mitigation, prescription drug monitoring program data, and urine drug screening prior to opioid prescribing. A quality improvement project was conducted to evaluate the number of pharmacist-provided opioid risk mitigation recommendations implemented by orthopedic providers for patients who underwent total hip or knee arthroplasty at SFVHCS. Summary A pharmacist-led workflow for completing risk mitigation reviews was developed in collaboration with orthopedic providers, and urine drug screening was added to the preoperative laboratory testing protocol. The following recommendations were communicated via electronic medical record: limit postoperative opioids to a 7- or 14-day supply based on risk of suicide and/or overdose, offer naloxone and a medication disposal bag, and order a urine drug screen if not already completed. Risk reviews were completed for 75 patients. Among 64 patients with 2-month postdischarge data available, 88% (7 of 8) of 7-day and 79% (44 of 56) of 14-day opioid supply recommendations were implemented; 41% (26 of 59) of recommendations to issue a medication disposal bag, 17% (2 of 12) recommendations to order a missing urine drug screen, and 9% (5 of 55) of recommendations to offer naloxone were implemented. Conclusion Pharmacist-performed risk mitigation reviews paired with individualized recommendations led to high rates of orthopedic provider acceptance of limiting postdischarge opioid day supplies for patients who had total hip or knee arthroplasty. Alternative strategies may increase access to naloxone. Future research should examine the impact of risk mitigation tools in reducing prescribing of long-term opioid therapy and adverse events among orthopedic surgical patients.

scholarly journals Does Lidocaine Cause False Positive Results on Cocaine Urine Drug Screen?

2019 ◽  
Vol 15 (4) ◽  
pp. 255-261 ◽  
Author(s):  
Eungjae Kim ◽  
Brian Patrick Murray ◽  
Maryam Salehi ◽  
Tim P. Moran ◽  
Joseph E. Carpenter ◽  
...  
Keyword(s):  
False Positive ◽  
Drug Screen ◽  
Urine Drug Screen ◽  
Urine Drug ◽  
Positive Results

scholarly journals Changes in urine drug screen results on a labor unit over two years

2022 ◽  
Vol 226 (1) ◽  
pp. S653-S654
Author(s):  
Bree A. Porcelli ◽  
Xiao Yu Wang ◽  
Nandini Raghuraman ◽  
Ebony B. Carter ◽  
Anthony O. Odibo ◽  
...  
Keyword(s):  
Drug Screen ◽  
Urine Drug Screen ◽  
Urine Drug

Abnormal movements and diaphragmatic flutter in a case of suspected induced illness

2021 ◽  
Vol 14 (4) ◽  
pp. e236962
Author(s):  
Rebecca Arvier ◽  
Thomas Clayton ◽  
Monique Dade ◽  
Rahul S Joshi
Keyword(s):  
Breathing Pattern ◽  
Tertiary Hospital ◽  
Drug Screen ◽  
Urine Drug Screen ◽  
Breathing Patterns ◽  
Abnormal Movements ◽  
Urine Drug ◽  
Conscious Level ◽  
Abnormal Breathing ◽  
Initial Results

A 6-month-old girl presented to hospital via ambulance with a decreased conscious level (initial Glasgow Coma Scale of 3) and an abnormal breathing pattern described as diaphragmatic flutter. She then developed abnormal movements and continued to have episodes of fluctuating conscious levels so was transferred to a tertiary hospital paediatric intensive care unit for further investigation. During her 16-day stay in hospital, she continued to experience discrete episodes of drowsiness, bradycardia, unusual breathing patterns and abnormal movements which were associated with agitation, tachycardia, hypertension and insomnia. The patient underwent extensive investigation for her symptoms and, after some delay in waiting for initial results before considering a urine drug screen, she was ultimately found to have lisdexamfetamine and clonidine in her urine drug screen. Her symptoms subsequently resolved after her mother’s visits were restricted.

Pregabalin for the discontinuation of long-term benzodiazepines use: An assessment of its effectiveness in daily clinical practice

2012 ◽  
Vol 27 (4) ◽  
pp. 301-307 ◽  
Author(s):  
J. Bobes ◽  
G. Rubio ◽  
A. Terán ◽  
G. Cervera ◽  
V. López-Gómez ◽  
...  
Keyword(s):  
Success Rate ◽  
Rating Scale ◽  
Adjunctive Treatment ◽  
Drug Screen ◽  
Urine Drug Screen ◽  
Success Rates ◽  
Urine Drug ◽  
Benzodiazepine Dependence ◽  
Benzodiazepine Withdrawal

AbstractPurposeTo evaluate the effectiveness and tolerability of pregabalin in the management of the discontinuation of benzodiazepines in long-term users.Subjects and methodsWe performed a 12-week, prospective, uncontrolled, non-interventional, and observational study in patients aged 18 years old or above, who met DSM-IV-TR criteria for benzodiazepine dependence without other major psychiatry disorder. Evaluations included the Benzodiazepine Withdrawal Symptom Questionnaire, the Hamilton Anxiety Rating Scale, the Clinical Global Impression Scale, and the Sheehan Disability Scale. A urine drug screen for benzodiazepines was performed at baseline and every 4 weeks thereafter. The primary effectiveness variable was success rate, defined as achievement of benzodiazepine-free status at week 12 according to the urine drug screen.Results and discussionThe mean dose at week 12 was 315 (±166) mg/day. The success rate of the benzodiazepine taper in the primary efficacy population (n = 282) was 52% (95% confidence interval [CI], 46–58). Success rates for women and men were 58% (95% CI, 49–67) and 46% (95% CI, 38–55), respectively. The success rates did not differ according to either the benzodiazepine of abuse or the presence of other substance use disorders. Significant and clinically relevant improvements were observed in withdrawal and anxiety symptoms, as well as in patients’ functioning. At week 12, tolerability was rated as good or excellent by 90% and 83% of the clinicians and patients, respectively.ConclusionOur results suggest that pregabalin is an efficacious and well-tolerated adjunctive treatment for benzodiazepine withdrawal.

scholarly journals False-positive phencyclidine (PCP) on urine drug screen attributed to desvenlafaxine (Pristiq) use

2017 ◽  
pp. bcr-2017-222106 ◽  
Author(s):  
T Michael Farley ◽  
Emily N Anderson ◽  
Jade N Feller
Keyword(s):  
False Positive ◽  
Drug Screen ◽  
Urine Drug Screen ◽  
Urine Drug

scholarly journals Current drug use and lack of HIV virologic suppression: point-of-care urine drug screen versus self-report

2014 ◽  
Vol 14 (1) ◽  
Author(s):  
Han-Zhu Qian ◽  
Valerie J Mitchell ◽  
Sally Bebawy ◽  
Holly Cassell ◽  
Gina Perez ◽  
...  
Keyword(s):  
Drug Use ◽  
Point Of Care ◽  
Self Report ◽  
Drug Screen ◽  
Virologic Suppression ◽  
Urine Drug Screen ◽  
Current Drug ◽  
Urine Drug
Sign in / Sign up

Export Citation Format

Share Document